Oxidative Stress and Pathological Glutamate Release in Stroke

Information

  • Research Project
  • 10103863
  • ApplicationId
    10103863
  • Core Project Number
    R01NS111943
  • Full Project Number
    5R01NS111943-03
  • Serial Number
    111943
  • FOA Number
    PA-18-484
  • Sub Project Id
  • Project Start Date
    2/1/2019 - 5 years ago
  • Project End Date
    1/31/2024 - 8 months ago
  • Program Officer Name
    BOSETTI, FRANCESCA
  • Budget Start Date
    2/1/2021 - 3 years ago
  • Budget End Date
    1/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    03
  • Suffix
  • Award Notice Date
    1/27/2021 - 3 years ago
Organizations

Oxidative Stress and Pathological Glutamate Release in Stroke

SUMMARY Stroke is the fifth leading cause of death and the leading cause of adult long-term disability in the U.S. and other industrialized nations. Yet only one therapeutic agent (the clot-dissolving drug tPA) is approved for acute treatment. Among the critical injurious factors in stroke, oxidative stress is thought to contribute to the terminal steps of tissue damage. Antioxidants and free radical scavengers are highly protective in animal stroke models. Yet, for poorly understood reasons, they have shown limited or no benefits in clinical trials. In the prior NIH- sponsored project, we collected strong data which may help to revise our understanding of the mechanisms contributing to oxidative injury in ischemia: (1) In a rat model of stroke, we found that the superoxide dismutase (SOD) mimetic tempol was more protective than clinically used antioxidants. (2) Potent protection by tempol correlated with reduction of redox-sensitive glutamate release in the ischemic penumbra. (3) Glutamate release was mediated by at least two redox-sensitive mechanisms: volume-regulated anion channels (VRAC) and Ca2+- dependent changes in membrane permeability. (4) The glutamate-permeable VRAC was composed of proteins from the leucine-rich repeat-containing family 8 (LRRC8). We have assembled a synergistic team of investi- gators and propose to use highly innovative molecular and animal tools to test the HYPOTHESIS that reactive oxygen species (ROS, particularly superoxide anions) propagate and amplify stroke injury via stimulation of redox-sensitive glutamate release in the clinically relevant penumbra. In the planned studies we will address the following critical questions: (1) Is the LRRC8A-containing VRAC a viable target for neuroprotection in stroke? (2) Is glutamate release via the heteromeric LRRC8 channels responsible for tissue injury? (3) What is the chemical nature of the tempol-targeted ROS and the cellular site of their production? (4) Does glutamate release via VRAC drive disruption at the neurovascular interface (changes in blood flow and BBB integrity)? The immediate goal of the proposed work is to identify new molecular mechanisms that govern oxidative brain injury and determine the protective actions of antioxidants. Our long-term objective is to provide a blueprint for the development of new effective stroke therapies based on SOD mimetics and/or VRAC blockers.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R01
  • Administering IC
    NS
  • Application Type
    5
  • Direct Cost Amount
    265548
  • Indirect Cost Amount
    140982
  • Total Cost
    406530
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
    NINDS:406530\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    NOMD
  • Study Section Name
    Neural Oxidative Metabolism and Death Study Section
  • Organization Name
    ALBANY MEDICAL COLLEGE
  • Organization Department
  • Organization DUNS
    190592162
  • Organization City
    ALBANY
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    122083479
  • Organization District
    UNITED STATES